263 related articles for article (PubMed ID: 20735441)
1. Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?
Steiner I; Rosenberg G; Wirguin I
Clin Exp Immunol; 2010 Oct; 162(1):32-40. PubMed ID: 20735441
[TBL] [Abstract][Full Text] [Related]
2. Autoimmunity and cytokines in Guillain-Barré syndrome revisited: review of pathomechanisms with an eye on therapeutic options.
Ebrahim Soltani Z; Rahmani F; Rezaei N
Eur Cytokine Netw; 2019 Mar; 30(1):1-14. PubMed ID: 31074417
[TBL] [Abstract][Full Text] [Related]
3. Guillain-barré syndrome: modern theories of etiology.
Hardy TA; Blum S; McCombe PA; Reddel SW
Curr Allergy Asthma Rep; 2011 Jun; 11(3):197-204. PubMed ID: 21451970
[TBL] [Abstract][Full Text] [Related]
4. Transplanted human fecal microbiota enhanced Guillain Barré syndrome autoantibody responses after Campylobacter jejuni infection in C57BL/6 mice.
Brooks PT; Brakel KA; Bell JA; Bejcek CE; Gilpin T; Brudvig JM; Mansfield LS
Microbiome; 2017 Aug; 5(1):92. PubMed ID: 28789710
[TBL] [Abstract][Full Text] [Related]
5. Role of cytokines and Toll-like receptors in the immunopathogenesis of Guillain-Barré syndrome.
Nyati KK; Prasad KN
Mediators Inflamm; 2014; 2014():758639. PubMed ID: 25614713
[TBL] [Abstract][Full Text] [Related]
6. Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination.
Israeli E; Agmon-Levin N; Blank M; Chapman J; Shoenfeld Y
Clin Rev Allergy Immunol; 2012 Apr; 42(2):121-30. PubMed ID: 20890797
[TBL] [Abstract][Full Text] [Related]
7. Zika autoimmunity and Guillain-Barré syndrome.
Katz I; Gilburd B; Shovman O
Curr Opin Rheumatol; 2019 Sep; 31(5):484-487. PubMed ID: 31246623
[TBL] [Abstract][Full Text] [Related]
8. A review of the role of genetic factors in Guillain-Barré syndrome.
Safa A; Azimi T; Sayad A; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2021 May; 71(5):902-920. PubMed ID: 33029737
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of Guillain-Barré syndrome.
Hughes RA; Hadden RD; Gregson NA; Smith KJ
J Neuroimmunol; 1999 Dec; 100(1-2):74-97. PubMed ID: 10695718
[TBL] [Abstract][Full Text] [Related]
10. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.
Chi LJ; Wang HB; Zhang Y; Wang WZ
J Neuroimmunol; 2007 Dec; 192(1-2):206-14. PubMed ID: 17997492
[TBL] [Abstract][Full Text] [Related]
11. IL-23/IL-17 immune axis in Guillain Barré Syndrome: Exploring newer vistas for understanding pathobiology and therapeutic implications.
Debnath M; Nagappa M; Murari G; Taly AB
Cytokine; 2018 Mar; 103():77-82. PubMed ID: 29331587
[TBL] [Abstract][Full Text] [Related]
12. Th1/Th2/Th17/Treg cytokines in Guillain-Barré syndrome and experimental autoimmune neuritis.
Zhang HL; Zheng XY; Zhu J
Cytokine Growth Factor Rev; 2013 Oct; 24(5):443-53. PubMed ID: 23791985
[TBL] [Abstract][Full Text] [Related]
13. The immunobiology of Guillain-Barré syndromes.
Willison HJ
J Peripher Nerv Syst; 2005 Jun; 10(2):94-112. PubMed ID: 15958123
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in exon 2 of CD1 genes are associated with susceptibility to Guillain-Barré syndrome.
Liu H; Xing Y; Guo Y; Liu P; Zhang H; Xue B; Shou J; Qian J; Peng J; Wang R; Gao Y; Fang S
J Neurol Sci; 2016 Oct; 369():39-42. PubMed ID: 27653862
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis E virus-associated Guillain-Barre syndrome: Revision of the literature.
Liu H; Ma Y
Brain Behav; 2020 Jan; 10(1):e01496. PubMed ID: 31828968
[TBL] [Abstract][Full Text] [Related]
16. Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions.
Blum S; McCombe PA
J Peripher Nerv Syst; 2014 Jun; 19(2):88-103. PubMed ID: 25039604
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategies in the Guillain-Barré syndrome.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):159-68. PubMed ID: 12894381
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to Guillain-Barré syndrome is associated to polymorphisms of CD1 genes.
Caporale CM; Papola F; Fioroni MA; Aureli A; Giovannini A; Notturno F; Adorno D; Caporale V; Uncini A
J Neuroimmunol; 2006 Aug; 177(1-2):112-8. PubMed ID: 16820217
[TBL] [Abstract][Full Text] [Related]
19. Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.
Magira EE; Papaioakim M; Nachamkin I; Asbury AK; Li CY; Ho TW; Griffin JW; McKhann GM; Monos DS
J Immunol; 2003 Mar; 170(6):3074-80. PubMed ID: 12626563
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive cytokine profiling provides evidence for a multi-lineage Th responses in Guillain Barré Syndrome.
Debnath M; Nagappa M; Talukdar PM; Subbanna M; Sundaravadivel P; Shivakumar V; Dutta D; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Taly AB
Cytokine; 2018 Oct; 110():58-62. PubMed ID: 29704819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
